Immunome Inc [IMNM] stock is trading at $16.05, up 5.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMNM shares have gain 10.01% over the last week, with a monthly amount glided 3.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on May 31, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $27. Previously, JP Morgan started tracking the stock with Overweight rating on April 30, 2024, and set its price target to $24. On April 15, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $35 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $30 on January 29, 2024. Wedbush initiated its recommendation with a Outperform and recommended $12 as its price target on December 19, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 29, 2021, and assigned it a price target of $35.
Immunome Inc [IMNM] stock has fluctuated between $4.50 and $30.96 over the past year. Currently, Wall Street analysts expect the stock to reach $34 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $16.05 at the most recent close of the market. An investor can expect a potential return of 111.84% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Immunome Inc [NASDAQ:IMNM] reported sales of 12.68M for the trailing twelve months, which represents a drop of -56.47%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -18.71%, Pretax Profit Margin comes in at -18.29%, and Net Profit Margin reading is -18.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -2.21 and Total Capital is -0.82. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.48 points at the first support level, and at 14.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.37, and for the 2nd resistance point, it is at 16.68.
Ratios To Look Out For
For context, Immunome Inc’s Current Ratio is 10.18. Further, the Quick Ratio stands at 10.18, while the Cash Ratio is 8.77. Considering the valuation of this stock, the price to sales ratio is 75.91, the price to book ratio is 3.35.
Transactions by insiders
Recent insider trading involved SIEGALL CLAY B, President and CEO, that happened on May 21 ’24 when 20434.0 shares were purchased. Director, BIENAIME JEAN JACQUES completed a deal on May 21 ’24 to buy 2000.0 shares. Meanwhile, President and CEO SIEGALL CLAY B bought 79566.0 shares on May 20 ’24.
